An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change ...
Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and ...
Response rates to second-line STS therapies, including pazopanib, are typically <10% with median PFS <5 months, underscoring demand for predictive biomarkers. Transcriptomic profiling of 11 paired pre ...
Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
The Women’s Health Initiative, launched in 1991 across 40 centers with >161,000 participants, materially influenced practice ...
The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...
Disease-modifying antirheumatic drug (DMARD) and tumor necrosis factor (TNF) cycling is a real and well-documented problem in ...
The FDA approved Moderna’s Biologics License Application (BLA) for its mRNA-based flu vaccine, mRNA-1010 (mFlusiva; Moderna), ...
A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results